Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.

Zheng W, Rutter CM.

Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1722-30. doi: 10.1158/1055-9965.EPI-12-0561. Epub 2012 Aug 21.

2.

A comparison of fecal occult-blood tests for colorectal-cancer screening.

Allison JE, Tekawa IS, Ransom LJ, Adrain AL.

N Engl J Med. 1996 Jan 18;334(3):155-9.

3.

Evaluation of new occult blood tests for detection of colorectal neoplasia.

St John DJ, Young GP, Alexeyeff MA, Deacon MC, Cuthbertson AM, Macrae FA, Penfold JC.

Gastroenterology. 1993 Jun;104(6):1661-8.

PMID:
8500724
5.

Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.

Jouve JL, Remontet L, Dancourt V, Lejeune C, Benhamiche AM, Faivre J, Esteve J.

Br J Cancer. 2001 Jun 1;84(11):1477-81.

6.

Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.

Kershenbaum A, Flugelman A, Lejbkowicz F, Arad H, Rennert G.

Eur J Cancer. 2013 Mar;49(4):923-30. doi: 10.1016/j.ejca.2012.09.020. Epub 2012 Oct 22.

PMID:
23099005
7.
8.

Screening for colorectal cancer. A comparison of 3 fecal occult blood tests.

Levin B, Hess K, Johnson C.

Arch Intern Med. 1997 May 12;157(9):970-6.

PMID:
9140267
9.

Analysis of screening data: colorectal cancer.

Gyrd-Hansen D, Søgaard J, Kronborg O.

Int J Epidemiol. 1997 Dec;26(6):1172-81.

PMID:
9447396
10.

Colocare self-test versus Hemoccult II Sensa for fecal occult blood testing.

Foliente RL, Wise GR, Collen MJ, Abdulian JD, Chen YK.

Am J Gastroenterol. 1995 Dec;90(12):2160-3.

PMID:
8540507
11.

A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy.

Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, Zuckerman GR, Rockey DC.

Am J Gastroenterol. 2000 May;95(5):1331-8.

PMID:
10811348
12.

A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population.

Wong BC, Wong WM, Cheung KL, Tong TS, Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, Lai KC, Hu WH, Chan CK, Lam SK.

Aliment Pharmacol Ther. 2003 Nov 1;18(9):941-6.

13.

Comparison of the specificity and sensitivity of Hemoccult and HemoQuant in screening for colorectal neoplasia.

St John DJ, Young GP, McHutchison JG, Deacon MC, Alexeyeff MA.

Ann Intern Med. 1992 Sep 1;117(5):376-82.

PMID:
1503328
15.
16.

Systematic review with meta-analysis: faecal occult blood tests show lower colorectal cancer detection rates in the proximal colon in colonoscopy-verified diagnostic studies.

Hirai HW, Tsoi KK, Chan JY, Wong SH, Ching JY, Wong MC, Wu JC, Chan FK, Sung JJ, Ng SC.

Aliment Pharmacol Ther. 2016 Apr;43(7):755-64. doi: 10.1111/apt.13556. Epub 2016 Feb 9. Review.

PMID:
26858128
17.

Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME; Colorectal Cancer Study Group.

N Engl J Med. 2004 Dec 23;351(26):2704-14.

18.

Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II.

Kristinsson J, Nygaard K, Aadland E, Barstad S, Sauar J, Hofstad B, Stray N, Stallemo A, Haug B, Ugstad M, Tøn H, Fuglerud P.

Digestion. 2001;64(2):104-10.

PMID:
11684824
19.

Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program.

Petrelli N, Michalek AM, Freedman A, Baroni M, Mink I, Rodriguez-Bigas M.

Surg Oncol. 1994 Feb;3(1):27-36.

PMID:
8186868
20.

Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.

Prevost TC, Launoy G, Duffy SW, Chen HH.

Am J Epidemiol. 1998 Sep 15;148(6):609-19.

PMID:
9753016

Supplemental Content

Support Center